4		

2

# Rapid Biphasic Decay of Intact and Defective HIV DNA

### **Reservoir During Acute Treated HIV Disease**

3

Alton Barbehenn<sup>1</sup>, Lei Shi<sup>2</sup>, Junzhe Shao<sup>2</sup>, Rebecca Hoh<sup>1</sup>, Heather M. Hartig<sup>1</sup>, Vivian Pae<sup>1</sup>,
Sannidhi Sarvadhavabhatla<sup>1</sup>, Sophia Donaire<sup>1</sup>, Caroline Sheikhzadeh<sup>1</sup>, Jeffrey Milush<sup>5</sup>, Gregory
M. Laird<sup>3</sup>, Mignot Mathias<sup>3</sup>, Kristen Ritter<sup>3</sup>, Michael Peluso<sup>1</sup>, Jeffrey Martin<sup>4</sup>, Frederick Hecht<sup>1</sup>,
Christopher Pilcher<sup>1</sup>, Stephanie E. Cohen<sup>1,6</sup>, Susan Buchbinder<sup>6</sup>, Diane Havlir<sup>1</sup>, Monica
Gandhi<sup>1</sup>, Timothy J. Henrich<sup>5</sup>, Hiroyu Hatano<sup>1</sup>, Jingshen Wang<sup>2</sup>, Steven G. Deeks<sup>1</sup>, and Sulggi
A. Lee<sup>\*1</sup>

10

<sup>1</sup>Department of Medicine, Division of HIV, Infectious Diseases & Global Medicine, University of
 California San Francisco, San Francisco, CA 94110, USA. <sup>2</sup>Department of Biostatistics,
 University of California Berkeley, Berkeley, CA 94110, USA. <sup>3</sup>AccelevirDiagnostics, Baltimore,
 MD 21202, USA. <sup>4</sup>Department of Biostatistics & Epidemiology, University of California San
 Francisco, CA 94158, USA. <sup>5</sup>Department of Medicine, Division of Experimental Medicine,
 University of California San Francisco, San Francisco, CA 94110, USA. <sup>6</sup>San Francisco
 Department of Public Health, San Francisco, CA 94102, USA.

18

19 <sup>#</sup>Co-Lead Authors: Alton Barbehenn and Lei Shi

<sup>\*</sup>Corresponding Author: sulggi.lee@ucsf.edu

### 21 ABSTRACT

Antiretroviral therapy (ART) is not a cure. Upon ART cessation, virus rapidly rebounds from 22 latently-infected cells ("the HIV reservoir"). The reservoir is largely stabilized at the time of ART 23 24 initiation and then decays slowly. Here, leveraging >500 longitudinal samples from 67 people 25 with HIV (PWH) treated during acute infection, we developed a novel mathematical model to predict reservoir decay using the intact proviral DNA assay (IPDA) from peripheral CD4+ T cells. 26 27 Nonlinear generalized additive models adjusted for initial CD4+ T count, pre-ART viral load, and timing of ART initiation demonstrated rapid biphasic decay of intact DNA (week 0-5: t<sub>1/2</sub> ~0.71 28 months; week 5-24: t<sub>1/2</sub> ~3.9 months) that extended out to 1 year of ART, with similar trends for 29 defective DNA. Predicted reservoir decay were faster for participants individuals with earlier 30 31 timing of ART initiation, higher initial CD4+ T cell count, and lower pre-ART viral load. These 32 estimates are ~5-fold faster than prior reservoir decay estimates among chronic-treated PWH. 33 Thus, these data add to our limited understanding of host viral control at the earliest stages of 34 HIV reservoir stabilization, potentially informing future HIV cure efforts aimed at diverse, global 35 population of PWH initiating ART at varying stages of disease.

36

37 Abstract Word Count (approx. 150): 198

39 **Title Word Count** (max 15): 15

40 Manuscript Word Count (5000; Methods 3,000 words): 4,122

41 Keywords: acute HIV; antiretroviral therapy (ART); HIV reservoir decay; pre-exposure
42 prophylaxis (PrEP)

43 CONFLICTS: The authors do not have a commercial or other association that might pose a
 44 conflict of interest.

45 FUNDING: This work was supported in part by the National Institutes of Health: K23GM112526 46 (SAL), the DARE Collaboratory (UM1AI164560; SGD), the AccelevirDx HIV Reservoir Testing 47 Resource (U24AI143502; GML), and NIH/NIAID R01A141003 (TJH). This work was also supported by the amfAR Research Consortium on HIV Eradication a.k.a. ARCHE (108072-50-48 RGRL; SGD), the Bill & Melinda Gates Foundation (INV-002703; SGD), and investigator-49 50 initiated research grants from ViiV Healthcare (A126326; SAL) and Gilead Sciences (IN-US-236-1354; SAL). The content of this publication does not necessarily reflect the views or policies 51 52 of the Department of Health and Human Services, the San Francisco Department of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the 53 54 U.S. Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 55

56 Previous presentation: Preliminary data were presented in July 2023, as a poster presentation
57 at the International AIDS Society (IAS) conference in Brisbane, Australia.

**Reprints:** Reprint requests can be directed to Dr. Sulggi Lee, the corresponding author (contact
information above).

60 Acknowledgements:

The authors wish to acknowledge the participation of all the study participants who contributed to this work as well as the clinical research staff of the UCSF Treat Acute HIV and SCOPE

63 cohorts who made this research possible. All funders had no role in study design, data 64 collection and analysis, decision to publish, or preparation of the manuscript. All authors provided critical feedback in finalizing the report. HH, SGD, and SAL conceived and designed 65 the study. HH, SGD, and SAL obtained funding to support the clinical enrollment of study 66 67 participants, and SAL and SGD obtained funding to support characterization of the HIV reservoir. SEC, SB, DH, and MG facilitated coordination with San Francisco Department of 68 69 Public Health and Ward 86 clinical services to link patients into care and provided critical feedback on the clinical management of acute HIV. SAL, RH, SGD, TJH, HMH, SS, SD, and VP 70 71 coordinated the collection, management, and quality control processes for the clinical data, and 72 SAL, SGD, JM, FH, and CP provided biospecimens. JM and TJH performed biospecimen 73 processing, GML, MM, and KR performed the HIV reservoir assays. LS developed the initial 74 decay models, under the guidance of SAL and JW, and AB and SAL further modified these 75 models under the guidance of JW, LS, and JS. GML, MM, KR, LS, JS, JW, and SAL analyzed 76 the HIV reservoir data. SAL, AB, LS, and JW wrote the report. SS, SD, VP, CS, LS, JS, JW, and 77 SAL finalized data visualization for the manuscript. All authors provided critical feedback in 78 finalizing the manuscript.

### 79 INTRODUCTION

Despite over four decades of research, we do not yet have an HIV cure. While 80 antiretroviral therapy (ART) is able to suppress virus to undetectable levels, virus rapidly 81 82 rebounds from latently-infected cells ("the HIV reservoir") within weeks of ART interruption.<sup>1-8</sup> 83 Thus, a major goal is to eradicate and/or accelerate the decay of the reservoir in order to achieve clinical remission. However, HIV cure trials to date have largely failed to demonstrate a 84 85 clinically meaningful reduction in the size of the HIV reservoir and/or lead to sustained ART-free remission.<sup>9-12</sup> The majority of these trials have been conducted among people with HIV (PWH) 86 treated during chronic infection and were administered therapeutic interventions long after the 87 reservoir was established (i.e., several years after initiating ART)<sup>13-18</sup>. Recent combination 88 therapy trials (e.g., broadly neutralizing antibodies given with ART) have yielded more promising 89 90 results, and a few participants have demonstrated evidence of extended ART-free viral control<sup>19-</sup> <sup>21</sup>, but the mechanisms by which these small number of participants exhibit enhanced viral 91 92 control remain unclear.

One possibility is that since PWH treated during chronic HIV often have larger 93 reservoirs<sup>22-29</sup> and exhausted/dysfunctional immune responses<sup>30-32</sup> (due to prolonged periods of 94 95 untreated HIV infection), that demonstrating measurable HIV remission from these small trials may have been more challenging. Indeed, individuals who initiate ART "earlier" (within 6 months 96 97 after infection) may be more likely to become "post-treatment controllers" (PTCs), rare PWH who, for unclear reasons, are able to control virus without ART following a brief of initial ART 98 suppression.<sup>33</sup> Thus, different host factors, such as timing of ART initiation in relation to 99 100 chronicity of HIV infection, initial CD4+ T cell count, or pre-ART HIV viral load, may have 101 profound impact on estimating HIV reservoir decay rates, and yet there are limited data 102 modeling decay rates while accounting for these factors. Such information would be immensely useful in future HIV cure trials to compare expected reservoir decay rates in comparison to 103

104 curative interventions and allow generalizability of findings to a more global population of PWH105 (treated during acute or chronic infection).

While there have now been a handful of studies modeling how guickly the HIV reservoir 106 107 decays during prolonged ART (studies spanning nearly 20 years on ART)<sup>34-37</sup>, there have been 108 no studies modeling HIV reservoir decay rates after acute treated HIV infection. Here, leveraging ~500 longitudinal blood measurements of the HIV reservoir, we developed a novel 109 110 mathematical model of reservoir decay among 67 participants from the UCSF Treat Acute HIV cohort initiating ART within 100 days of the estimated date of HIV infection.<sup>38</sup> These data 111 demonstrate for the first time that the reservoir decays significantly faster in acute compared to 112 chronic treated PWH initiating ART.<sup>3</sup> Our partially parameterized mathematical model flexibly 113 estimated the rate of change of the HIV reservoir to include participant-level random effects (to 114 115 account for heterogeneity in decay rates) as well as key clinical covariates (initial CD4+ T count, 116 pre-ART viral load, and days since estimated date of HIV infection).

We fit various mono-, bi-, and triphasic decay curves for both HIV "intact" (infected cells 117 118 harboring intact viral sequences able to produce infectious virions) and "defective" (the majority 119 of the HIV reservoir but incapable of producing infectious virions) DNA. For both intact and defective DNA, we observed clear biphasic decay patterns with an initial rapid first phase of 120 decay (which was nearly identical to previous estimates in chronic treated PWH initiating ART<sup>3</sup>) 121 122 followed by a second slower phase of decay (~5-fold faster that previously reported in chronic PWH initiating ART). Furthermore, these decay rates were significantly faster among individuals 123 with known clinical factors associated with enhanced host viral control: higher initial CD4+ T cell 124 count, earlier initiation of ART, and lower pre-ART viral loads.<sup>22,23,34,39,40</sup> These data are the first 125 to our knowledge to describe a predictive mathematical model to describe HIV reservoir decay 126 127 rates during acute treated HIV.

128

129 **RESULTS** 

### 130 Characteristics of study participants

131 A total of 67 adults (83% of those screened) with a new diagnosis of acute HIV (<100 days between the estimated date of detected HIV infection to the baseline study visit/ART 132 133 initiation) were included in the UCSF Treat Acute HIV cohort (Table 1, Supplementary Figure 1) <sup>41</sup>. All 67 participants completed follow-up in the study for the full 24 weeks. A large 134 proportion (65.7%) of participants co-enrolled in our longitudinal UCSF SCOPE HIV cohort and 135 136 remained in study for additional follow-up, with study visits approximately every 3-4 months thereafter. Follow-up for the current analysis included longitudinal sampling for a median of 0.81 137 years. The estimated dates of detected infection (EDDI) were calculated to determine recency 138 of infection using the Infection Dating Tool (https://tools.incidence-estimation.org/idt/) 42 139 (Supplementary Figure 2). These estimates were then used to estimate acute HIV Fiebig 140 141 stages <sup>4344</sup>. Consistent with our San Francisco-based study population, participants were mostly male (97%) and reflected local and national racial/ethnic trends of higher incident acute HIV in 142 these populations <sup>45</sup>. Baseline study visit HIV-1 antigen/antibody (Architect) and HIV-1 antibody 143 144 (Geenius) testing demonstrated 27% and 28% false negative/indeterminate rates, respectively, 145 consistent with our San Francisco Department of Public Health (SFDPH) reported estimates for new acute HIV diagnoses <sup>46</sup> (Supplementary Figure 4). Genotype data (Monogram) were 146 available for a subset of 57 participants; 77% had wild-type HIV, 9% had M184V/I mutations (all 147 148 were reported among participants citing prior and/or current PrEP use), and 14% had evidence of possible partner-transmitted resistance mutations (based on referral of newly diagnosed 149 partners within our cohort and/or SFDPH partner tracing <sup>46</sup>). 150

Our cohort also reflected a high proportion of self-reported prior PrEP use (42% reporting ever use while 20% reported PrEP use in the past 10 days), reflecting San Francisco's early and widespread adoption of PrEP <sup>46</sup>. All PrEP reported in this study was oral PrEP with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), as this was the only form clinically available during the study period. Among individuals reporting overlapping PrEP use within 10

days from their estimated date of HIV acquisition (using self-reported PrEP use and the infection dating tool as described in the Methods <sup>42</sup>), six participants were deemed to have probable HIV acquisition while on PrEP (median baseline plasma  $log_{10}HIV$  RNA = 2.2 copies/mL), which was approximately ~3  $log_{10}$  lower than those not reporting PrEP overlap (**Table 1**). One participant was estimated to have acquired HIV in the setting of therapeutic PrEP concentrations (confirmed by plasma and hair ART concentrations), as described in our previous publication <sup>47</sup>.

162

### 163 Rapid biphasic decay of intact and defective DNA

We estimated the rate of change of HIV intact and defective DNA as log<sub>10</sub> copies per 10<sup>6</sup> 164 peripheral CD4+ T cells (quantified using the IPDA), as well as the influence of clinical 165 covariates on the rate of HIV DNA change. A median of 2 x 10<sup>6</sup> CD4+ T cells per sample 166 167 (median viability of 97%) was recovered from peripheral CD4+ T cells isolated by negative 168 immunomagnetic selection. Duration of ART was used as the primary predictor to allow for time-169 varying estimation of changes within each person across the sampling timepoints. The rate of 170 change was estimated for the primary outcome of HIV intact DNA, as well as the secondary 171 outcome of defective DNA (3' defective, 5' defective, and total combined defective provirus). We 172 initially modeled HIV intact and defective DNA using a linear effect of time on ART (which assumes a constant rate of change regardless of the duration of viral suppression). However, 173 174 we observed evidence of nonlinearity, and thus, instead of fitting a single constant rate of decline, we fit nonlinear generalized additive models to estimate the appropriate nonparametric 175 176 relationship for each predictor term.

177 Clinical covariates of age, gender, pre-ART CD4+ T cell count, pre-ART viral load, and 178 timing of ART initiation (number of weeks since estimated date of infection) were tested for 179 inclusion in these models. Final models included terms for initial CD4+ T cell count, pre-ART 180 viral load, and timing of ART initiation. **Figure 4** illustrates that of the three clinical covariates, 181 only timing of ART initiation changes the shape of the reservoir decay, whereas initial CD4+ T

182 cell count and pre-ART viral load account for patient-level variation. Additionally, we added 183 individual participant-level random effects into regression models to account for heterogeneity in 184 outcome measures within individuals (see Statistical Methods). Given the small number of 185 participants reporting PrEP use within 10 days of HIV acquisition (Table 1), inclusion of this 186 parameter as a covariate in the model and sensitivity analyses excluding these individuals did not change results, and thus was not included as a covariate in final models. In addition, 187 188 participants reporting potential PrEP overlap did not clearly fall in the lower range of reservoir 189 measurements, but rather, were dispersed among the range of HIV intact and defective DNA values (Supplementary Figure 5). 190

Therefore, we then fit various mono-, bi-, and triphasic decay curves for both HIV intact 191 192 and defective DNA using semiparametric generalized additive models that introduced up to two inflection points, tau ( $\tau$ ), delineating distinct exponential decay phases (see Statistical 193 194 **Methods**). We then estimated the decay model's inflection points  $\tau$  by minimizing prediction 195 errors as measured by leave-one-out mean absolute deviation (MAD) and leave-one-out mean squared error (MSE) approaches (Figure 2, Supplementary Figure 7). For HIV intact DNA, we 196 197 found that the biphasic model best fit our data, while for defective DNA, the biphasic and triphasic models were relatively equivalent in performance (Supplementary Figure 6). A 198 199 biphasic model outperformed a monophasic decay model for both intact and defective DNA. 200 These analyses demonstrated that  $\tau = 5$  weeks closely fit our data using this biphasic model. To 201 ensure that the selected  $\tau = 5$  was not influenced by potential outlier data, we performed three different sensitivity analyses excluding (1) individuals reporting prior PrEP use within 10 days of 202 203 estimated date of HIV infection, (2) participants with plasma viral load "blips" (defined as a onetime viral load >1000 copies/mL or two consecutive viral loads >100 copies/mL between weeks 204 0-24), and (3) participants with sudden increases in HIV intact DNA (defined as >50% increase 205 206 between two consecutive measurements of HIV intact DNA during weeks 0-24). These

sensitivity analyses demonstrated that  $\tau = 5$  is a reasonable choice for the mode l's inflection point and that the model estimates were unchanged after excluding these potential outliers.

209 Based on our final selected multivariate model, we observed a rapid biphasic decay of 210 both intact and defective DNA during acute treated HIV infection, with an initial steep decay until 211 approximately 5 weeks of ART, followed by a slower decay (Figure 1a). For example, for HIV intact DNA, we estimated that the first phase of reservoir decay had an estimated half-life  $(t_{1/2})$ 212 ~0.70 (95% confidence interval [CI] = 0.59, 0.82) months in unadjusted models and a  $t_{1/2}$  ~0.71 213 214 (95%CI = 0.60, 0.82) months in models adjusted for clinical covariates. This was followed by a slower second decay phase after ~5 weeks of ART with a  $t_{1/2}$  ~3.61 (95%Cl = 2.81, 4.42) 215 216 months in unadjusted models and a  $t_{1/2} \sim 3.86$  (95%CI = 2.99, 4.72) months in models adjusted 217 for clinical covariates. Similar first phase (weeks 0-5) decay rates were observed for HIV defective DNA in unadjusted ( $t_{1/2} \sim 0.34$ , 95% CI = 0.29, 0.38) and adjusted ( $t_{1/2} \sim 0.34$ , 95% CI = 218 0.29, 0.39) models but estimates were less stable for the second phase of defective DNA decay 219 220 due to considerable variability in these data (Figure 1, Supplementary Tables 1-2). Thus, we 221 did not observe discernable differences in decay rates for HIV intact versus defective DNA in the first five weeks after ART initiation, in contrast to prior reservoir decay studies among 222 chronic treated PWH during nearly 20 years of ART<sup>34-36,48</sup>, although we did see a discernable 223 224 differences in decay rates for HIV intact versus defective DNA from weeks 5-24 that seems to continue out to a year (Supplementary Figure 7). 225

For all models, fitted values closely predicted observed values for both intact and defective DNA (**Supplementary Figure 10**). We further validated our models using our clinical data to determine whether our model captured expected clinical relationships. Our model tells us that for every additional week ART initiation is delayed, the half-life for the first phase of HIV intact reservoir decay increases by ~0.02 months; similarly, the defective reservoir's half-life increases by ~0.01 months. Importantly, our model tells us that the timing of ART initiation has a larger impact on the second phase of HIV reservoir decay. During weeks 5-24, our model

233 predicts an increase in intact reservoir decay half-life of ~0.27 months for every week delay in ART initiation and no significant change to the defective HIV reservoir (Supplementary Table 234 3). Concretely, this means that a patient who initiates ART 30 days post infection has an 235 average intact HIV reservoir decay half-life of ~2.5 months while a patient who initiates ART 100 236 237 days post infection has an average intact HIV reservoir decay half-life of ~6.3 months; as suggested in Supplementary Figure 7, this may continue out to a year on ART. Clinical 238 239 validation of the initial CD4+ T cell count and pre-ART viral load terms is more straightforward because they are only used to account for participant-level variation, not changes in half-life. 240 Our model tells us that both lower pre-ART viral load and higher initial CD4+ T counts were 241 242 associated with lower intact and defective HIV DNA reservoirs (Supplementary Table 4). Finally, using bootstrapping methods (random sampling of the clinical covariates to compute 243 244 model predictions for 300 new participants) we estimated HIV DNA intact and defective counts 245 and then averaged the model predictions within strata (tertiles) of each clinical parameter (e.g., average HIV intact DNA decay rate for the first, second, and third tertiles of pre-ART viral loads 246 (Figure 5). These analyses clearly demonstrated that our model predicts lower HIV intact and 247 248 defective DNA reservoirs for individuals with higher initial CD4+ T cell count and lower pre-ART 249 viral load, and the HIV intact and defective DNA reservoirs decayed more rapidly for earlier 250 timing of ART initiation.

251

### 252 **DISCUSSION**

The HIV reservoir is established within days after initial viral infection<sup>49-51</sup>, and although ART can suppress virus to undetectable levels in the blood, persistently cells are a source of viral rebound when therapy is interrupted. A major goal of HIV cure strategies is to induce ARTfree remission<sup>52</sup>. Thus, clearly defining complex reservoir decay dynamics at the time of HIV reservoir establishment – including how key host factors such as the timing of ART initiation, initial CD4+ T cell count, and pre-ART viral load influence these decay rates – will be important

259 in interpreting HIV cure trial results. Potential promising therapeutic interventions may be 260 optimally studied in specific patient populations, but results from such studies can still inform future therapies for all PWH. For example, chronic treated PWH may benefit from the same 261 262 curative interventions as acute treated PWH but might require adjunctive therapies to reverse cell exhaustion<sup>53-55</sup>. Here, using a unique cohort of individuals followed longitudinally since acute 263 264 HIV infection and immediate ART initiation, we observed a clear biphasic decay of the reservoir 265 during the first year of therapy. Decay rates were accelerated among individuals with clinical factors associated with enhanced viral control (higher initial CD4+ T cell count, lower pre-ART 266 viral load, and earlier timing of ART initiation)<sup>22,23,34,39,40</sup> and were faster than prior reports among 267 chronic treated PWH initiating ART<sup>3</sup>. 268

Our model allowed flexible estimation of HIV intact and defective decay rates while 269 270 adjusting for clinical covariates, in contrast prior studies which mostly fit fully parameterized, mixed effects models<sup>3,48,56,57</sup>. For example, with HIV intact DNA, the observed initial rapid phase 271 272 was estimated to have a half-life  $(t_{1/2})$  of 0.71 months until approximately 5 weeks of ART. This was then followed by a slower second phase of decay with a half-life of 3.86 months. Strikingly, 273 274 our estimated decay rate of HIV intact DNA during the first phase of decay is nearly identical to estimates of HIV intact DNA among chronic treated PWH initiating ART in a prior study ( $t_{1/2}$  = 275 0.43 months)<sup>3</sup>. However, our estimates for the second phase of decay ( $t_{1/2}$  = 3.9 months) were 276 277 ~5-fold faster than reported their study of chronic treated PWH, where the second phase of decay was estimated to be much longer  $(t_{1/2} = 19 \text{ months})^3$ . This initial rapid decay phase is 278 thought to reflect death of productively infected cells in the setting of rapid antigen reduction 279 with ART initiation<sup>4</sup> and thus similarly rapid decay rates immediately after ART initiation may be 280 similar for PWH who start therapy during acute, as well as chronic infection. Meanwhile, the 281 282 second phase of decay is thought to reflect a "contraction phase" when activated cells shift to a more memory phenotype<sup>58</sup> and therefore, the larger differences that we observed in our cohort 283

compared to earlier findings in chronic-treated PWH may indicate a unique phase during which
 intervention may considerably influence HIV reservoir decay rates with earlier ART initiation.

PWH treated during acute infection have been shown to have less exhausted/relatively 286 intact host immune responses due to earlier removal of antigen and reduction of subsequent 287 inflammation and immune activation. <sup>59</sup> For these reasons, the study of acute treated PWH 288 provides a unique opportunity to identify the optimal timing, potential "windows of time" during 289 290 which intervention with immunomodulatory agents may have a greater impact on reducing the reservoir size. Most (but not all) studies have shown that those who initiate ART during acute 291 292 and early infection also have smaller reservoirs than PWH who initiated ART during chronic infection <sup>22-26,28,50,51,60</sup>. Given the limited data demonstrating reservoir decay rates during acute 293 and early infection <sup>26,50,61,62</sup>, none of which included statistical modeling incorporating key clinical 294 295 parameters such as timing of ART initiation, initial CD4+ T cell count, and pre-ART viral load, 296 our data add considerable insight to our current understanding of the timing and modification of 297 early HIV reservoir establishment and stabilization. Nonetheless, there are a wealth of other 298 invaluable HIV cohorts, such as the RV254/SEARCH 010 study, that if these data are compiled 299 across studies, may further inform our understanding of how guickly the reservoir decays, and how factors such as ART initiation during acute infection may alter those trajectories. Indeed, in 300 the RV254/SEARCH 010 study, the presented HIV reservoir data (their study measured 301 302 integrated and unintegrated HIV DNA) plotted longitudinally, seem to indicate that similar decay patterns might be observed in their cohort as well. <sup>50</sup> Acute treated PWH in the study 303 demonstrated rapid decay of both integrated and unintegrated HIV DNA while among chronic 304 treated PWH in their study, only a modest decline in integrated HIV DNA was observed. (The 305 latter may be an artifact of the previously noted observation that among chronic PWH, the 306 307 majority of integrated HIV DNA tend to be latent or defective, rather than productively infected, as in acute PWH). 50 308

medRxiv preprint doi: https://doi.org/10.1101/2024.03.27.24304867; this version posted March 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

309 While there have been limited studies describing HIV reservoir decay rates in acute treated PWH, there now been several studies describing HIV reservoir decay rates during 310 chronic treated HIV (followed as long as ~20 years of ART). These studies have now 311 312 demonstrated that cells harboring "intact" provirus (i.e., infected cells capable of producing 313 infectious virus) decay more quickly than defective provirus (infected cells that make up the majority of the reservoir and contain deletions and/or mutated viral sequences<sup>63,64</sup>) during long-314 315 term ART<sup>34-37</sup>. While our data are unable to yet describe decay rates past 1 year of ART, our study offers for the first time a detailed estimation of HIV reservoir decay rates in the first few 316 weeks to months of ART initiation during acute HIV. While we did not observe discernable 317 318 differences between HIV intact and defective decay rates as previously described among chronic PWH, <sup>34-36,48</sup> we did find that HIV defective DNA was much more "noisy" than intact DNA 319 320 (as shown in Figure 2), and thus the lack of statistical significance in the second phase of decay 321 reported here may be further investigated in future larger studies. Indeed, the putative 322 mechanism underlying the differential decay rates of HIV intact and defective reservoir during 323 long-term ART is thought to be due to selective immune clearance over time; cells harboring 324 inducible "replication-competent" virus may be more readily detected by host immune surveillance and cleared.<sup>34-36,48,65,66</sup> It is unclear if these same factors are at play as early as 5 325 weeks after initiating ART during acute HIV infection. 326

Studies estimating HIV reservoir decay rates in chronic PWH have shown that the HIV intact reservoir decays with a  $t_{1/2}$  of ~44 months. <sup>67,68</sup> Subsequent studies studying individuals as far out as ~20 years of ART suggest that this  $t_{1/2}$  further slows to ~224-276 months after about 7 years of ART.<sup>34-36,48</sup> Interestingly, these long-term follow-up studies have found that during this late phase of reservoir decay, some individuals appear to demonstrate a plateau, or even a slight increase, in their HIV intact reservoir size. The reasons for this are unclear but some have argued that this may be due to a "tipping point" at which the host immune response has cleared

the majority of the intact reservoir in the body and is then counterbalanced by ongoing cell
 proliferation. <sup>48</sup>

While we were able to perform an in-depth statistical modeling study, leveraging unique 336 acute treated participant samples and a large number of longitudinal HIV reservoir 337 338 measurements, our study has several limitations that deserve mention. While the peripheral HIV reservoir largely reflect infected-cell populations originating from tissues reservoir, <sup>49,50,69,70</sup> 339 340 we only included peripheral CD4+ T cell HIV reservoir measures in our model. In addition, while 341 we used the widely utilized IPDA (a high throughput assay that can be performed on this large number of samples), alternative assays, such as near-full length proviral sequencing or QVOA, 342 would have been informative to further interpret our findings (if these were able to be performed 343 at the scale required for this large number of samples). However, HIV intact DNA measured 344 345 using the IPDA has been shown to closely reflect trends resulting from these other assays, even considering the known enrichment of integrated forms of HIV DNA observed in acute 346 PWH.<sup>50</sup> As with all molecular assays for HIV, certain polymorphisms at primer or probe binding 347 sites can impact IPDA assay performance. In this study, we observed IPDA signal failure for 6 348 349 of 67 participants (8.9%) – a rate consistent recent reports on very large cohorts of PWH from North America and Europe where subtype B predominates (6-7%)<sup>34,71</sup>. While the IPDA does not 350 perfectly discriminate intact from defective proviruses, the cross sectional and longitudinal 351 352 correlations between IPDA and QVOA measurements of the HIV reservoir strongly support the use of the higher throughput IPDA in large scale studies of proviral decay dynamics. We did not 353 354 include parameters for potential influences from changes in clonal landscape over time as our study did not include HIV integration analyses. However, the clonal landscape at the time of 355 acute HIV is extremely diverse, and we hypothesize that this effect is more likely to have higher 356 357 impact after longer duration of ART suppression. Future models should include these parameters to formally test this hypothesis. Finally, there are few highly characterized acute HIV 358 cohorts to date, and each study possesses unique host and viral characteristics making direct 359

360 cross-cohort comparisons challenging. These cohort-specific factors include host genetics, 361 socio-behavioral demographics (our study included mostly men who have sex with men), clinical 362 practices and public policy guidelines for ART initiation, and viral subtype (mostly subtype B in our study). Our HIV reservoir decay model should be further validated in these global 363 364 populations, including individuals initiating treatment during chronic HIV, which represents the 365 majority of people currently living with HIV. Overall, these data encourage future collaborative 366 work to determine decay dynamics across global populations so that future cure strategies may 367 be effective across clades and in people with larger reservoirs, exhausted immune responses 368 who initiated ART during chronic HIV.

369

### 370 METHODS

### 371 Study participants

Individuals with newly diagnosed acute HIV (<100 days from estimated date of infection) 372 373 were enrolled in the UCSF Treat Acute HIV cohort between December 1, 2015 to November 30, 374 2020 and co-enrolled in the UCSF SCOPE HIV cohort, an ongoing longitudinal study of over 375 2,500 PWH to characterize the natural history of HIV disease. Eligible participants were consented, provided same-day ART initiation with tenofovir/emtricitabine (TDF/FTC, then 376 TAF/FTC once available in 2016) + dolutegravir (DTG) and linked to clinical care <sup>46</sup>. Individuals 377 378 reporting concomitant PrEP use (<100 days from any potential exposure to HIV by history and/or clinical test results) were also started on darunavir+ritonavir (DRV/r) as a fourth drug, 379 which was continued until confirmation of baseline HIV genotyping test results (Monogram 380 381 Biosciences, South San Francisco, CA, U.S.A.). Additional ART changes necessary for clinical 382 care (e.g., laboratory abnormalities, drug-drug interactions, and/or participant preference) were honored and adjusted during the period of study. Participants signed a release of information 383

384 which allowed clinical data extraction to determine prior HIV negative test results from the 385 SFDPH, as well as additional HIV test results.

386 Study participants were seen for monthly study visits for the first 24 weeks and then every 3-4 months thereafter. Inclusion criteria for the study were prior HIV negative testing 387 within the last 90 days, laboratory-confirmed HIV-1 infection by antibody/antigen and/or plasma 388 389 HIV RNA assay, and willingness to be participate in the study for at least 24 weeks. Participants 390 with severe renal or hepatic impairment, concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory drugs in the preceding 90 days prior to study entry, 391 392 pregnant or breastfeeding women, or participants unwilling to agree to the use a double-barrier 393 method of contraception throughout the study period, were excluded. For each study participant, using the Infection Dating Tool (https://tools.incidence-estimation.org/idt/)<sup>42</sup>, the estimated date 394 of detected HIV infection (EDDI), along with a "confidence interval" for early probable (EP-EDDI) 395 and late probable (LP-EDDI) date was calculated using each participant's prior clinical HIV test 396 397 results, as well the study baseline HIV test results. At each visit, detailed interviews included 398 questions regarding current medications, medication adherence, intercurrent illnesses, and hospitalizations were performed. In addition, peripheral blood sampling at each visit was 399 performed to measure plasma HIV RNA, CD4+ T cell count, and clinical labs (complete blood 400 count, metabolic panel), as well as blood for storage - PBMCs and plasma. For a subset of 401 402 individuals who reported potential PrEP overlap with HIV EDDI, participants were consented and co-enrolled in the SeroPrEP study and dried blood spot and hair were collected to confirm 403 PrEP use. Finally, some individuals were invited to participate in optional sub-studies, which 404 405 included leukapheresis and lymphoid tissue sampling (rectal and ileal biopsies, lymph node fine 406 needle aspirate) after 12 months of ART suppression (data not included here in this paper). All participants provided written informed consent, and the institutional review board of UCSF 407 408 approved the research.

409

### 410 HIV reservoir quantification

There is currently no "gold standard" for measuring the HIV reservoir. Moreover, the HIV 411 412 reservoir largely consists of "defective" virus that harbors mutations prohibiting the production of infectious virus <sup>63,64</sup>. The frequencies of HIV intact and defective (3' and 5') DNA were quantified 413 using the intact proviral DNA assay (PDA), as previously described <sup>72</sup>. Briefly, CD4+ T cells 414 were isolated from cryopreserved PBMCs (EasySep Human CD4+ T cell Enrichment Kit, 415 Stemcell Technologies), with cell count, viability, and purity assessed by flow cytometry both 416 417 before and after selection. Negatively selected CD4+ T cells were recovered for the samples, 418 and genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen). DNA concentration 419 and quality were determined by fluorometry (Qubit dsDNA BR Assay Kit, Thermo Fisher 420 Scientific) and ultraviolet-visible (UV/VIS) spectrophotometry (QIAxpert, Qiagen). The frequency 421 of "intact" HIV provirus (i.e., estimating the potentially replication-competent reservoir) was 422 determined using two multiplex digital droplet polymerase chain reaction (ddPCR) assays performed in parallel: (1) the HIV-1 Proviral Discrimination reaction which distinguishes intact 423 424 from defective provirus via two strategically placed amplicons in HIV psi and RRE regions as 425 well as a hypermutation discrimination probe, and (2) the Copy Reference/Shearing reaction, which quantifies DNA shearing and input diploid cell equivalents using the human RPP30 gene 426 <sup>72</sup>. All ddPCR reactions were assembled via automated liquid handles to maximize 427 reproducibility and analyzed using the BioRad QX200 AutoDG Digital Droplet PCR system 428 (BioRad). Up to 700 ng of genomic DNA were analyzed per reaction, and final input DNA 429 concentrations were dependent upon the concentration of recovered DNA. Samples were batch 430 processed and analyzed, including negative controls from uninfected donors and J-Lat full-431 432 length clone 6.3 (E. Verdin, Gladstone Institutes and UCSF, San Francisco, CA, USA) cells as positive controls, as previously described. Across the >500 IPDA measurements performed, we 433

interrogated a median of 4.8 x 10<sup>5</sup> CD4+ T cell genomes per assay and observed a median 434 435 DNA shearing index (DSI) of 0.40.

436

### 437 **Statistical Methods**

438 We developed a novel semiparametric biphasic decay model to estimate the rate of change of HIV DNA over time in log<sub>10</sub> copies per 10<sup>6</sup> CD4+ T cells: 439

 $\log_{10}(I_{it}) \sim f_1(T_{it}; \tau, \beta_1, \beta_2) + E_i \cdot f_2(T_{it}; \tau, \beta_3, \beta_4) + f_3(C_i) + f_4(V_i) + \mu_i. \#(1)$ 

In equation (1),  $I_{it}$  represents either the intact or defective HIV DNA counts, of the *i*-th 440 participant at t-th visit. The number of weeks since ART initiation is denoted  $T_{it}$ . The model 441 442 additionally controls for baseline clinical information defined as the initial CD4+ T cell count,  $C_i$ , 443 pre-ART viral load,  $V_i$ , and the estimated time between HIV infection and ART initiation,  $E_i$ . The delay in ART initiation is centered to have a mean of zero for later analysis; this offset is 444 445 approximately 60 days in our cohort. Participant-level random effects are denoted  $\mu_i$ . Building on existing models, <sup>3,48</sup> we parameterize the decay as a continuous, linear spline with a single 446 knot at  $\tau$ :  $f_1(T_{it}; \tau, \beta_1, \beta_2) = \beta_1 \cdot \min\{T_{it}, \tau\} + \beta_2 \cdot \min\{T_{it} - \tau, 0\}$ . Using this parameterization, we 447 can directly interpret  $\beta_1$  as the decay rate before  $\tau$  and  $\beta_2$  as the decay rate after  $\tau$ ; we use the 448 same parameterization for  $f_2(T_{it}; \tau, \beta_3, \beta_4)$  but with different  $\beta$  values. We use a cubic spline with 449 20 regularly spaced knots for both  $f_3(C_i)$  and  $f_4(V_i)$ . Once  $\tau$  is fixed, model fitting is performed 450 using least-squares regression. When testing our model against monophasic and triphasic 451 models, we used either linear terms or linear splines with two knots for  $f_1$  and  $f_2$  respectively. 452

The estimation of the inflection point,  $\tau$ , is done by minimizing the model's mean 453 454 absolute prediction error. We fixed a grid of candidate  $\tau$  values from 0 weeks to 25 weeks, by half-week. The mean absolute prediction error was estimated using leave-one-out cross-455 456 validation calculated as

$$Error(\tau) = \sum_{i,t} \left| \log_{10}(I_{it}) - \log_{10}\left(\hat{I}_{it}^{(-i)}\right) \right|, \#(2)$$

457 where  $\hat{I}_{it}^{(-i)}$  denotes the predicted HIV DNA counts for patient *i* at time *t* using the model fit with 458 every patient except patient *i*. This loss metric was also used to estimate the two knots in the 459 triphasic model. Akaike information criteria (AIC) was used to compare the fits of the mono-, bi-, 460 and triphasic models.

Half-life estimates and their confidence intervals are computed using the multivariate delta method. During the first decay phase, we are interested in estimating the baseline half-life in months and the adjustment to the half-life in months due to delay in ART initiation. The halflife (in months) before  $\tau$  is calculated as

$$t_{\frac{1}{2}}(E_i) = -\frac{0.25 \log_{10}(2)}{\beta_1 + \beta_2 E_i} = -\frac{0.25 \log_{10}(2)}{\beta_1} + \frac{0.25 \log_{10}(2) \beta_2 E_i}{\beta_1^2} + O(E_i^2), \#(3)$$

where the second equality is the degree-one Taylor series about  $E_i = 0$ ; this is the reason we center  $E_i$  in our pre-processing. Thus we are interested in estimating the base-line half-life  $g_1(\beta_1, \beta_3) = -0.25 \log_{10}(2) / \beta_1$  and the adjustment to half-life for every week delay in ART  $g_2(\beta_1, \beta_2) = 0.25 \log_{10}(2) \beta_2 / \beta_1^2$ . Appealing the asymptotic normality of our parameter estimates and the multivariate delta method, we get the following asymptotic distribution for our half-life estimates:

$$\sqrt{n} \left( \begin{bmatrix} g_1(\widehat{\beta_1}, \widehat{\beta_2}) \\ g_2(\widehat{\beta_1}, \widehat{\beta_2}) \end{bmatrix} - \begin{bmatrix} g_1(\beta_1, \beta_2) \\ g_2(\beta_1, \beta_2) \end{bmatrix} \right) \stackrel{d}{\to} N \left( \begin{pmatrix} 0 \\ 0 \end{pmatrix}, J \Sigma J^T \right) \#(4)$$
$$J = 0.25 \log_{10}(2) \begin{bmatrix} \frac{1}{\beta_1^2} & 0 \\ -2\frac{\beta_2}{\beta_1^2} & \frac{1}{\beta_1^2} \end{bmatrix} \#(5)$$

where  $\Sigma$  is the covariance between  $\beta_1$  and  $\beta_2$ , and *J* is the Jacobian matrix of  $g(\beta_1, \beta_2)$ . We plugin  $\hat{\Sigma}$ , along with  $\hat{\beta_1}$  and  $\hat{\beta_2}$  from our model to estimate the asymptotic confidence intervals for base-line half-life and adjustment to half-life for delay in ART initiation. Percent decay per week

- 474 before  $\tau$  is calculated using the transformation  $h(\beta_1) = -100 (2^{\beta_1} 1)$ ; the negative sign
- 475 accounts for the directionality of the decay. These calculations are the same for estimates of the

476 half-life

after

τ.

## Table 1. Baseline Characteristics of the UCSF Treat Acute Study Population. Medians with

interquartile ranges and frequencies with percentages are shown.


UCSF Treat Acute HIV Cohort	N=67
Days from estimated HIV acquisition to ART initiation	32.0 (22.3 - 89.8)
Initial CD4+ T-cell count (cells/mm <sup>3</sup> )	505 (350 - 670)
Pre-ART plasma HIV RNA (log <sub>10</sub> copies)	4.85 (3.69 - 5.65)
Age	30.0 (25.5 – 38.0)
Gender	
Male	65 (97.0%)
Female	1 (0.01%)
Transgender Woman	1 (0.01%)
Race/ethnicity	
White	21 (31.8%)
Latinx	20 (30.3%)
Asian	14 (21.2%)
Black	10 (15.2%)
Other	1 (1.5%)
Prior pre-exposure prophylaxis (PrEP)	28 (41.8%)
HIV acquisition/PrEP overlap <10 days	14 (20.1%)
PrEP initiated but already acquired HIV	8 (11.9%)
HIV acquired on PrEP <sup>a</sup>	6 (9.0%)
Referral HIV testing sites	
SF Department Public Health (%)	28 (41.8%)
Community-Based Organization (%)	29 (43.2%)
Private Health Clinics (%)	10 (14.9%)
Unstably housed	2 (3.0%)

<sup>a</sup> Median baseline plasma log<sub>10</sub>HIV RNA = 2.2 copies/mL.


### Figure 1. Fitted models match observed HIV reservoir patterns for HIV intact and defective DNA.

The decay patterns for each participant are shown as thin grey lines, while the decay pattern for the model-predicted average participant is shown as the thick black lines. Biphasic decay patters were observed for HIV intact (left panel) and total combined (3' plus 5') defective (right panel) (a). For defective HIV DNA, the biphasic decay pattern was observed more strongly for 5' but also seen with 3' defective DNA (b). Average predicted participant predictions were made by taking the mean of  $E_i$  (estimated time between HIV infection and ART initiation),  $C_i$  (initial CD4+ T cell count), and  $V_i$  (log<sub>10</sub> pre-ART plasma viral load) across participants from our final model.


a.




b.



# Figure 2. An inflection point ( $\tau = 5$ weeks) was chosen from a grid from 0 weeks to 24 weeks, by half-weeks. Results are shown for both intact (a) and defective (b) HIV DNA decay models, respectively. The biphasic decay model's inflection point was tuned by estimating the $\tau$ that minimized prediction error measured by leave-one-out mean absolute error (MAE, upper panels) and leave-one-out mean squared error (MSE, lower panels). The best $\tau$ for each loss (red point) is shown in relation to the final model's selected inflection point of $\tau = 5$ weeks as reference (vertical dashed line).




**Figure 3.** Lower pre-ART viral load and higher initial CD4+ T counts are associated with lower HIV DNA reservoirs in fitted spline models. Fitted spline models with corresponding 95% confidence intervals for HIV intact (a) and defective (b) DNA plotted against log<sub>10</sub> pre-ART viral load (left panel) and initial CD4+ T cell count (right panel). The fitted spline models are plotted in red with corresponding 95% confidence intervals denoted by blue dashed lines. Lower intact HIV DNA reservoirs (a) were associated with lower pre-ART viral load and higher initial CD4+ T counts. For example, a participant with an initial CD4+ T cell count of 900 cells/mm<sup>3</sup> was predicted to have ~10 times smaller HIV intact reservoir than a participant with an initial CD4+ T cell count of 300 cells/mm<sup>3</sup>. Similar patterns were observed for HIV defective DNA, but the fitted splines were less linear (b).




**Figure 4**. **Clinical factors influence HIV intact and defective DNA decay rates**. Faster decay rates were observed among individuals with earlier ART initiation (a), higher CD4+ T cell count (b), and lower pre-ART viral load (c). Left and right panels show decay rates for HIV intact and defective DNA, respectively. Individual participant decay rates shown in thin black lines, and cohort medians shown by bold black solid or dashed lines.

a.




b.





C.







### 1 Figure 5. Model predictions demonstrate the impact of clinical factors on HIV DNA decay

2 rates. Average model predictions were made by bootstrapping 300 random participants and 3 predicting their HIV DNA counts, the model predictions were then averaged within each stratum 4 (tertiles of clinical predictors of HIV reservoir size: timing of ART initiation, initial CD4+ T cell 5 count, and pre-ART viral load). The strata for each key clinical parameter demonstrated that slight changes in these clinical parameters (e.g., by tertiles) significantly influence reservoir 6 7 decay rates for both intact and defective DNA. Predicted reservoir size 95% confidence limits 8 were narrower for the first phase of decay (weeks 0-5) relative to the second phase of decay 9 (weeks 5-24).

- 10
- 11 **a.**







### 23 **REFERENCES**

- 1 Chun, T. W. et al. Rebound of plasma viremia following cessation of antiretroviral
- 25 therapy despite profoundly low levels of HIV reservoir: implications for
- eradication. *AIDS* **24**, 2803-2808 (2010).
- 27 https://doi.org:10.1097/QAD.0b013e328340a239
- 28 2 Hocqueloux, L. *et al.* Long-term immunovirologic control following antiretroviral
- therapy interruption in patients treated at the time of primary HIV-1 infection.
- 30 *AIDS* **24**, 1598-1601 (2010). <u>https://doi.org:10.1097/qad.0b013e32833b61ba</u>
- 31 3 White, J. A. *et al.* Complex decay dynamics of HIV virions, intact and defective
- 32 proviruses, and 2LTR circles following initiation of antiretroviral therapy. *Proc Natl*
- 33 Acad Sci U S A **119** (2022). <u>https://doi.org:10.1073/pnas.2120326119</u>
- 34 4 Perelson, A. S. *et al.* Decay characteristics of HIV-1-infected compartments
- during combination therapy. *Nature* **387**, 188-191 (1997).
- 36 <u>https://doi.org:10.1038/387188a0</u>
- 5 Kwon, K. J. & Siliciano, R. F. HIV persistence: clonal expansion of cells in the
- 38 latent reservoir. *J Clin Invest* **127**, 2536-2538 (2017).
- 39 https://doi.org:10.1172/JCI95329
- 40 6 Finzi, D. & Siliciano, R. F. Viral dynamics in HIV-1 infection. Cell 93, 665-671
- 41 (1998). <u>https://doi.org:10.1016/s0092-8674(00)81427-0</u>
- 42 7 Chomont, N. *et al.* HIV reservoir size and persistence are driven by T cell survival
- 43 and homeostatic proliferation. *Nature medicine* **15**, 893-900 (2009).
- 44 <u>https://doi.org:10.1038/nm.1972</u>

- 45 8 Yukl, S. A. *et al.* Differences in HIV burden and immune activation within the gut
- 46 of HIV-positive patients receiving suppressive antiretroviral therapy. *The Journal*
- 47 of infectious diseases **202**, 1553-1561 (2010). <u>https://doi.org:10.1086/656722</u>
- 48 9 Archin, N. M. *et al.* Administration of vorinostat disrupts HIV-1 latency in patients
- 49 on antiretroviral therapy. *Nature* **487**, 482-485 (2012).
- 50 <u>https://doi.org:10.1038/nature11286</u>
- 51 10 Elliott, J. H. et al. Short-term administration of disulfiram for reversal of latent HIV
- 52 infection: a phase 2 dose-escalation study. *Lancet HIV* **2**, e520-529 (2015).
- 53 <u>https://doi.org:10.1016/S2352-3018(15)00226-X</u>
- 11 Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-
- virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a
- 56 phase 1/2, single group, clinical trial. *Lancet HIV* **1**, e13-21 (2014).
- 57 <u>https://doi.org:10.1016/S2352-3018(14)70014-1</u>
- 58 12 Elliott, J. H. *et al.* Activation of HIV transcription with short-course vorinostat in
- 59 HIV-infected patients on suppressive antiretroviral therapy. *PLoS pathogens* **10**,
- 60 e1004473 (2014). <u>https://doi.org:10.1371/journal.ppat.1004473</u>
- 13 Gay, C. L. et al. Assessing the impact of AGS-004, a dendritic cell-based
- 62 immunotherapy, and vorinostat on persistent HIV-1 Infection. Sci Rep 10, 5134
- 63 (2020). <u>https://doi.org:10.1038/s41598-020-61878-3</u>
- 64 14 Fidler, S. et al. Antiretroviral therapy alone versus antiretroviral therapy with a
- kick and kill approach, on measures of the HIV reservoir in participants with
- recent HIV infection (the RIVER trial): a phase 2, randomised trial. *Lancet* **395**,
- 67 888-898 (2020). <u>https://doi.org:10.1016/S0140-6736(19)32990-3</u>

- 68 15 Gutierrez, C. *et al.* Bryostatin-1 for latent virus reactivation in HIV-infected
- 69 patients on antiretroviral therapy. *AIDS* **30**, 1385-1392 (2016).
- 70 https://doi.org:10.1097/QAD.00000000001064
- 71 16 Vibholm, L. et al. Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts
- 72 Innate Immunity and Plasma Viremia in Individuals With Human
- <sup>73</sup> Immunodeficiency Virus Infection. *Clin Infect Dis* **64**, 1686-1695 (2017).
- 74 https://doi.org:10.1093/cid/cix201
- 75 17 Riddler, S. A. et al. Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune
- 76 Activation in Virally Suppressed Adults Living With Human Immunodeficiency
- 77 Virus-1. *Clin Infect Dis* **72**, e815-e824 (2021).
- 78 https://doi.org:10.1093/cid/ciaa1534
- 18 Elliott, J. H. et al. Short-term administration of disulfiram for reversal of latent HIV
- infection: a phase 2 dose-escalation study. *Lancet HIV* **2**, e520-529 (2015).
- 81 <u>https://doi.org:10.1016/S2352-3018(15)00226-X</u>
- 82 19 Bar, K. J. et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment
- 83 Interruption. *N Engl J Med* **375**, 2037-2050 (2016).
- 84 <u>https://doi.org:10.1056/NEJMoa1608243</u>
- 85 20 Gunst, J. D. et al. Early intervention with 3BNC117 and romidepsin at
- 86 antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized
- trial. Nat Med 28, 2424-2435 (2022). <u>https://doi.org:10.1038/s41591-022-02023-7</u>
- 88 21 Gunst, J. D. et al. in Conference on Retroviruses and Opportunistic Infections.
- 89 22 Archin, N. M. et al. Immediate antiviral therapy appears to restrict resting CD4+
- 90 cell HIV-1 infection without accelerating the decay of latent infection. *Proc Natl*

91 *Acad Sci U S A* **109**, 9523-9528 (2012).

92 <u>https://doi.org:10.1073/pnas.1120248109</u>

- 93 23 Buzon, M. J. et al. Long-term antiretroviral treatment initiated at primary HIV-1
- 94 infection affects the size, composition, and decay kinetics of the reservoir of HIV-
- 95 1-infected CD4 T cells. *J Virol* **88**, 10056-10065 (2014).
- 96 https://doi.org:10.1128/JVI.01046-14
- 97 24 Chun, T. W. *et al.* Early establishment of a pool of latently infected, resting
- 98 CD4(+) T cells during primary HIV-1 infection. *Proc Natl Acad Sci U S A* **95**,

99 8869-8873 (1998). <u>https://doi.org:10.1073/pnas.95.15.8869</u>

- 100 25 Strain, M. C. *et al.* Effect of treatment, during primary infection, on establishment
- and clearance of cellular reservoirs of HIV-1. *J Infect Dis* **191**, 1410-1418 (2005).
- 102 <u>https://doi.org:10.1086/428777</u>
- 103 26 Hocqueloux, L., Saez-Cirion, A. & Rouzioux, C. Immunovirologic control 24
- 104 months after interruption of antiretroviral therapy initiated close to HIV
- 105 seroconversion. *JAMA Intern Med* **173**, 475-476 (2013).

106 <u>https://doi.org:10.1001/jamainternmed.2013.2176</u>

- 107 27 Ananworanich, J. et al. Virological and immunological characteristics of HIV-
- infected individuals at the earliest stage of infection. *J Virus Erad* **2**, 43-48 (2016).
- 109 28 Ananworanich, J. et al. Impact of multi-targeted antiretroviral treatment on gut T
- cell depletion and HIV reservoir seeding during acute HIV infection. *PLoS One* **7**,
- 111 e33948 (2012). <u>https://doi.org:10.1371/journal.pone.0033948</u>
- 112 29 Deleage, C. et al. Impact of early cART in the gut during acute HIV infection. JCI
- 113 Insight 1 (2016). <u>https://doi.org:10.1172/jci.insight.87065</u>

- 114 30 Takata, H. et al. Long-term antiretroviral therapy initiated in acute HIV infection
- prevents residual dysfunction of HIV-specific CD8(+) T cells. *EBioMedicine* **84**,
- 116 104253 (2022). <u>https://doi.org:10.1016/j.ebiom.2022.104253</u>
- 117 31 Oxenius, A. *et al.* Early highly active antiretroviral therapy for acute HIV-1
- infection preserves immune function of CD8+ and CD4+ T lymphocytes. *Proc*
- 119 *Natl Acad Sci U S A* **97**, 3382-3387 (2000).
- 120 https://doi.org:10.1073/pnas.97.7.3382
- 121 32 Streeck, H. *et al.* Immunological and virological impact of highly active
- antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis **194**, 734-
- 123 739 (2006). <u>https://doi.org:10.1086/503811</u>
- 124 33 Namazi, G. *et al.* The Control of HIV After Antiretroviral Medication Pause
- 125 (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J
- 126 Infect Dis **218**, 1954-1963 (2018). <u>https://doi.org:10.1093/infdis/jiy479</u>
- 127 34 Peluso, M. J. et al. Differential decay of intact and defective proviral DNA in HIV-
- 128 1-infected individuals on suppressive antiretroviral therapy. *JCI Insight* **5** (2020).
- 129 <u>https://doi.org:10.1172/jci.insight.132997</u>
- 130 35 Gandhi, R. T. *et al.* Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral
- 131 Therapy. J Infect Dis 223, 225-233 (2021). <u>https://doi.org:10.1093/infdis/jiaa532</u>
- 132 36 Gandhi, R. T. et al. Varied Patterns of Decay of Intact Human Immunodeficiency
- 133 Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy. *J Infect Dis*
- 134 **227**, 1376-1380 (2023). <u>https://doi.org:10.1093/infdis/jiad039</u>

- 135 37 Antar, A. A. *et al.* Longitudinal study reveals HIV-1-infected CD4+ T cell
- dynamics during long-term antiretroviral therapy. *J Clin Invest* **130**, 3543-3559
- 137 (2020). <u>https://doi.org:10.1172/JCI135953</u>
- 138 38 Shi, L. et al. in International AIDS Society Conference on HIV Science.
- 139 39 Ananworanich, J. et al. HIV DNA Set Point is Rapidly Established in Acute HIV
- 140 Infection and Dramatically Reduced by Early ART. *EBioMedicine* **11**, 68-72
- 141 (2016). <u>https://doi.org:10.1016/j.ebiom.2016.07.024</u>
- 142 40 Crowell, T. A. *et al.* Virologic failure is uncommon after treatment initiation during
- 143 acute HIV infection. *AIDS* **30**, 1943-1950 (2016).
- 144 <u>https://doi.org:10.1097/QAD.00000000001148</u>
- Lee SA, H. T., Gandhi M, Coffey S, Harting H, Hoh R, Peluso MJ, Siegel D,
- 146 Crouch P, Scott H, Cohen SD, Sachdev D, Bacon O, Busch M, Pilcher C,
- Buchbinder S, Havlir DV, Deeks SG. in *International AIDS Society Conference*.
- 148 42 Grebe, E. *et al.* Interpreting HIV diagnostic histories into infection time estimates:
- analytical framework and online tool. *BMC Infect Dis* **19**, 894 (2019).
- 150 <u>https://doi.org:10.1186/s12879-019-4543-9</u>
- 151 43 Fiebig, E. W. et al. Dynamics of HIV viremia and antibody seroconversion in
- 152 plasma donors: implications for diagnosis and staging of primary HIV infection.
- 153 *AIDS* **17**, 1871-1879 (2003).
- 154 <u>https://doi.org:10.1097/01.aids.0000076308.76477.b8</u>
- Keele, B. F. *et al.* Identification and characterization of transmitted and early
- 156 founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci U S A*
- 157 **105**, 7552-7557 (2008). <u>https://doi.org:10.1073/pnas.0802203105</u>

- 158 45 Prevention., C. f. D. C. a. HIV Surveillance Report.
- 159 <u>http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html</u>. Published May 2022.
- 160 Accessed Nov 2, 2023., (2020).
- 161 46 Buchbinder, S. P. & Havlir, D. V. Getting to Zero San Francisco: A Collective
- 162 Impact Approach. *J Acquir Immune Defic Syndr* **82 Suppl 3**, S176-S182 (2019).
- 163 https://doi.org:10.1097/QAI.00000000002200
- 164 47 Cohen, S. E. et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant
- 165 HIV despite high adherence to daily pre-exposure prophylaxis: a case report.
- 166 *Lancet HIV* (2018). <u>https://doi.org:10.1016/S2352-3018(18)30288-1</u>
- 167 48 McMyn, N. F. et al. The latent reservoir of inducible, infectious HIV-1 does not
- decrease despite decades of antiretroviral therapy. *J Clin Invest* **133** (2023).
- 169 <u>https://doi.org:10.1172/JCI171554</u>
- Whitney, J. B. *et al.* Rapid seeding of the viral reservoir prior to SIV viraemia in
- 171 rhesus monkeys. *Nature* **512**, 74-77 (2014). <u>https://doi.org:10.1038/nature13594</u>
- 172 50 Leyre, L. *et al.* Abundant HIV-infected cells in blood and tissues are rapidly
- 173 cleared upon ART initiation during acute HIV infection. *Sci Transl Med* **12** (2020).
- 174 https://doi.org:10.1126/scitranslmed.aav3491
- 175 51 Ananworanich, J. et al. Virological and immunological characteristics of HIV-
- infected individuals at the earliest stage of infection. *J Virus Erad* **2**, 43-48 (2016).
- 177 52 Deeks, S. G. *et al.* Research priorities for an HIV cure: International AIDS Society
- 178 Global Scientific Strategy 2021. *Nat Med* **27**, 2085-2098 (2021).
- 179 <u>https://doi.org:10.1038/s41591-021-01590-5</u>

- 180 53 Gay, C. L. et al. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1
- 181 Infected Participants on Suppressive Antiretroviral Therapy. *J Infect Dis* **215**,
- 182 1725-1733 (2017). <u>https://doi.org:10.1093/infdis/jix191</u>
- 183 54 Gay, C. L. *et al.* Suspected Immune-Related Adverse Events With an Anti-PD-1
- 184 Inhibitor in Otherwise Healthy People With HIV. J Acquir Immune Defic Syndr 87,
- 185 e234-e236 (2021). <u>https://doi.org:10.1097/QAI.000000000002716</u>
- 186 55 Colston, E. et al. An open-label, multiple ascending dose study of the anti-CTLA-
- 187 4 antibody ipilimumab in viremic HIV patients. *PLoS One* **13**, e0198158 (2018).
- 188 <u>https://doi.org:10.1371/journal.pone.0198158</u>
- 189 56 Reeves, D. B. et al. Impact of misclassified defective proviruses on HIV reservoir
- 190 measurements. *Nat Commun* **14**, 4186 (2023). <u>https://doi.org:10.1038/s41467-</u>
- 191 <u>023-39837-z</u>
- 192 57 Reeves, D. B. et al. A majority of HIV persistence during antiretroviral therapy is
- due to infected cell proliferation. *Nat Commun* **9**, 4811 (2018).
- 194 <u>https://doi.org:10.1038/s41467-018-06843-5</u>
- 195 58 Shan, L. *et al.* Transcriptional Reprogramming during Effector-to-Memory
- 196 Transition Renders CD4(+) T Cells Permissive for Latent HIV-1 Infection.
- 197 Immunity 47, 766-775 e763 (2017). <u>https://doi.org:10.1016/j.immuni.2017.09.014</u>
- 198 59 Jain, V. et al. Antiretroviral therapy initiated within 6 months of HIV infection is
- associated with lower T-cell activation and smaller HIV reservoir size. *J Infect Dis*
- 200 **208**, 1202-1211 (2013). <u>https://doi.org:10.1093/infdis/jit311</u>

201	60	Henrich, T. J. et al. HIV-1 persistence following extremely early initiation of
202		antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
203		PLoS Med 14, e1002417 (2017). https://doi.org:10.1371/journal.pmed.1002417
204	61	Chun, T. W. et al. Decay of the HIV reservoir in patients receiving antiretroviral
205		therapy for extended periods: implications for eradication of virus. J Infect Dis
206		195, 1762-1764 (2007). https://doi.org:10.1086/518250
207	62	Jain, V., Hartogensis, W., Bacchetti, P., Hunt, P.W., Hatano, H., Sinclair, E.,
208		Epling, L., Lee, T-H., Busch, M., McCune, J.M., Pilcher, C.D., Hecht, F.M., and
209		Deeks, S.G Antiretroviral therapy initiated within 6 months of HIV infection is
210		associated with lower T-cell activation and smaller HIV reservoir size. Journal of
211		Infectious Diseases In press (2013).
212	63	Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent
213		reservoir increase barrier to HIV-1 cure. Cell 155, 540-551 (2013).
214		https://doi.org:10.1016/j.cell.2013.09.020
215	64	Bruner, K. M. et al. Defective proviruses rapidly accumulate during acute HIV-1
216		infection. Nat Med 22, 1043-1049 (2016). https://doi.org:10.1038/nm.4156
217	65	Pinzone, M. R. et al. Longitudinal HIV sequencing reveals reservoir expression
218		leading to decay which is obscured by clonal expansion. Nat Commun 10, 728
219		(2019). https://doi.org:10.1038/s41467-019-08431-7
220	66	Gondim, M. V. P. et al. Heightened resistance to host type 1 interferons
221		characterizes HIV-1 at transmission and after antiretroviral therapy interruption.
222		Sci Transl Med 13 (2021). https://doi.org:10.1126/scitranslmed.abd8179

- EXAMPLE 223 67 Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active
- antiretroviral therapy. *Science* **278**, 1295-1300 (1997).
- 225 <u>https://doi.org:10.1126/science.278.5341.1295</u>
- 226 68 Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent
- reservoir for HIV-1 in resting CD4+ T cells. *Nature medicine* **9**, 727-728 (2003).
- 228 https://doi.org:10.1038/nm880
- 229 69 Kumar, M. R. et al. Biphasic decay of intact SHIV genomes following initiation of
- antiretroviral therapy complicates analysis of interventions targeting the reservoir.
- 231 Proc Natl Acad Sci U S A **120**, e2313209120 (2023).
- 232 <u>https://doi.org:10.1073/pnas.2313209120</u>
- 233 70 Martin, A. R. *et al.* Similar Frequency and Inducibility of Intact Human
- Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. J Infect Dis
- 235 **224**, 258-268 (2021). <u>https://doi.org:10.1093/infdis/jiaa736</u>
- 236 71 Simonetti, F. R. *et al.* Intact proviral DNA assay analysis of large cohorts of
- people with HIV provides a benchmark for the frequency and composition of
- 238 persistent proviral DNA. *Proc Natl Acad Sci U S A* **117**, 18692-18700 (2020).
- 239 https://doi.org:10.1073/pnas.2006816117
- 240 72 Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent
- 241 HIV-1 proviruses. *Nature* **566**, 120-125 (2019). <u>https://doi.org:10.1038/s41586-</u>
- 242 <u>019-0898-8</u>
- 243
- 244
- 245
- 246

### 247 **FIGURE LEGENDS**

Table 1. Baseline Characteristics of the UCSF Treat Acute Study Population. Medians with
 interguartile ranges and frequencies with percentages are shown.

250

251 Figure 1. Fitted models match observed HIV reservoir patterns for HIV intact and defective DNA. The decay patterns for each participant are shown as thin grey lines, while the 252 decay pattern for the model-predicted average participant is shown as the thick black lines. 253 Biphasic decay patters were observed for HIV intact (left panel) and total combined (3' plus 5') 254 defective (right panel) (a). For defective HIV DNA, the biphasic decay pattern was observed 255 more strongly for 5' but also seen with 3' defective DNA (b). Average predicted participant 256 predictions were made by taking the mean of  $E_i$  (estimated time between HIV infection and ART 257 initiation),  $C_i$  (initial CD4+ T cell count), and  $V_i$  (log<sub>10</sub> pre-ART plasma viral load) across 258 259 participants from our final model.

260

Figure 2. An inflection point ( $\tau = 5$  weeks) was chosen from a grid from 0 weeks to 24 weeks, by half-weeks. Results are shown for both intact (a) and defective (b) HIV DNA decay models, respectively. The biphasic decay model's inflection point was tuned by estimating the  $\tau$ that minimized prediction error measured by leave-one-out mean absolute error (MAE, upper panels) and leave-one-out mean squared error (MSE, lower panels). The best  $\tau$  for each loss (red point) is shown in relation to the final model's selected inflection point of  $\tau = 5$  weeks as reference (vertical dashed line).

268

Figure 3. Lower pre-ART viral load and higher initial CD4+ T counts are associated with lower HIV DNA reservoirs in fitted spline models. Fitted spline models with corresponding 95% confidence intervals for HIV intact (a) and defective (b) DNA plotted against log<sub>10</sub> pre-ART

viral load (left panel) and initial CD4+ T cell count (right panel). The fitted spline models are
plotted in red with corresponding 95% confidence intervals denoted by blue dashed lines. Lower
intact HIV DNA reservoirs (a) were associated with lower pre-ART viral load and higher initial
CD4+ T counts. For example, a participant with an initial CD4+ T cell count of 900 cells/mm<sup>3</sup>
was predicted to have ~10 times smaller HIV intact reservoir than a participant with an initial
CD4+ T cell count of 300 cells/mm<sup>3</sup>. Similar patterns were observed for HIV defective DNA, but
the fitted splines were less linear (b).

279

Figure 4. Clinical factors influence HIV intact and defective DNA decay rates. Faster decay rates were observed among individuals with earlier ART initiation (a), higher CD4+ T cell count (b), and lower pre-ART viral load (c). Left and right panels show decay rates for HIV intact and defective DNA, respectively. Individual participant decay rates shown in thin black lines, and cohort medians shown by bold black solid or dashed lines.

285

Figure 5. Model predictions demonstrate the impact of clinical factors on HIV DNA decay 286 287 rates. Average model predictions were made by bootstrapping 300 random participants and 288 predicting their HIV DNA counts, the model predictions were then averaged within each stratum (tertiles of clinical predictors of HIV reservoir size: timing of ART initiation, initial CD4+ T cell 289 count, and pre-ART viral load). The strata for each key clinical parameter demonstrated that 290 slight changes in these clinical parameters (e.g., by tertiles) significantly influence reservoir 291 292 decay rates for both intact and defective DNA. Predicted reservoir size 95% confidence limits were narrower for the first phase of decay (weeks 0-5) relative to the second phase of decay 293 294 (weeks 5-24).

295

Supplementary Figure 1. The UCSF Treat Acute HIV cohort study participants. A total of
 67 participants met inclusion criteria for acute HIV, defined as <100 days since the estimated</li>

date of detected HIV infection (EDDI) using the Infection Dating Tool (<u>https://tools.incidence-estimation.org/idt/</u>). The numbers of study participants by Fiebig stages (I-V) of HIV recency are also shown (https://doi.org:10.1097/01.aids.0000076308.76477.b8). PrEP = Pre-exposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).

302

303 **Supplementary Figure 2. Calculation of estimated dates of detected HIV infection**. The 304 estimated dates of detected HIV infection (EDDI), along with a "confidence interval" for early 305 probable (EP-EDDI) and late probable (LP-EDDI) dates, were calculated using participants' 306 clinical test results as well as baseline study visit confirmatory assay results.

307

Supplementary Figure 3. Fiebig and race/ethnicity distribution within the UCSF Treat Acute HIV cohort. The distribution of study participants in the UCSF Treat Acute HIV cohort, by timing of ART initiation (a) and self-reported race/ethnicity (b). A total of 67 participants met inclusion criteria for acute HIV, defined as <100 days since the estimated date of detected HIV infection (EDDI) using the Infection Dating Tool (https://tools.incidence-estimation.org/idt/). The proportions of study participants by Fiebig stages (I-V) are also shown in (a).

314

Supplementary Figure 4. HIV-1/2 test results for study participants. The proportion of study participants with either negative and/or indeterminate test results for HIV-1/2 p24 antigen/antibody assay (Architect) (a) and HIV-1/2 differentiation (Geenius) antibody assay (b) at baseline study visit were consistent with rates with our San Francisco Department of Public Health rates (27% and 28%, respectively).

320

Supplementary Figure 5. Observed HIV intact and defective reservoir decays highlighting
 participants reporting a history of PrEP use. Most participants did not report PrEP overlap

near the time of HIV diagnosis (grey lines). A subset of participants reported PrEP overlap within 10 days of HIV diagnosis; N=6 participants acquired HIV while already taking PrEP (yellow lines) and N=8 participants were prescribed PrEP but were found to already have acquired HIV (blue lines).

327

Supplementary Figure 6. Semiparametric monophasic, biphasic, and triphasic 328 329 generalized additive model fit comparison suggest biphasic model has the most parsimonious fit. Infection points were selected by minimizing the leave-one-out prediction 330 331 mean absolute error (MAE) for each model and both HIV DNA assays. Tuning results for the triphasic model show that the best model (emphasized in red) either has two knots near each 332 other or one knot near zero (a) suggesting that it is similar in shape to a biphasic model; leave-333 334 one-out prediction mean squared error (MSE) is proved for extra support. The Akaike 335 information criteria (AIC) value and 95% confidence interval was then used to compare 336 monophasic, biphasic, and triphasic models for both assays (b). AIC estimates and confidence intervals were found by fitting models on 500 bootstrap resampled data sets. For both HIV intact 337 338 and defective DNA, the biphasic and triphasic models had relatively equivalent performance.

339

Supplementary Figure 7. Modeling using the full first year of data suggests reservoir 340 341 decay trends continue past the first 24 weeks on ART. 65.7% of the total study participants 342 continued in the study beyond 24 weeks. Observed HIV reservoir patterns are shown as thin 343 grey lines, while the decay pattern for the model-predicted average participant is shown as the thick black lines (a). Average predicted participant predictions were made by taking the mean of 344  $E_i$  (estimated time between HIV infection and ART initiation),  $C_i$  (initial CD4+ T cell count), and 345  $V_i$  (log<sub>10</sub> pre-ART plasma viral load) across participants. Model inflection point tuning is shown 346 347 for both intact (left panels) and defective (right panels) HIV DNA decay models, respectively (b). 348 The biphasic decay model's inflection point was tuned by estimating the  $\tau$  that minimized

prediction error measured by leave-one-out mean absolute deviation (MAE, upper panels) and leave-one-out mean squared error (MSE, lower panels). A grid of  $\tau$  values from weeks 0 to 52, by half-weeks, was considered as potential inflection points. The best  $\tau$  for each loss (red point) is shown in relation to the final model's selected inflection point of  $\tau = 5$  weeks as reference (vertical dashed line).

354

Supplementary Figure 8. Inflection point sensitivity analyses demonstrate some 355 variability when excluding populations of potential outliers. To test whether the final model 356 inflection point selection of  $\tau = 5$  weeks was influenced by potential outlier data we performed  $\tau$ 357 358 estimation on three clinically interesting sub-populations. Separate models were fit that excluded (a) participants reporting prior PrEP use (<10 days overlap between last PrEP use and 359 estimated date of detected HIV infection), (b) participants with plasma viral load "blips" (defined 360 361 as a one-time viral load >1000 copies/mL or two consecutive viral loads >100 copies/mL between weeks 0-24), and (c) participants with sudden increases in HIV intact DNA (defined as 362 363 >50% increase between two consecutive measurements of HIV intact DNA during weeks 0-24). 364 A regular grid of possible  $\tau$  was used (0-26 weeks by half-week) and the leave-one-out cross-365 validation (LOOCV) mean absolute prediction error (MAE) was computed for each candidate  $\tau$ . The model attaining the best prediction error is denoted with a red point and our selected 366 inflection point ( $\tau = 5$ ) is shown with a dashed vertical line. Refer to **Supplementary Table 2** to 367 get the sample size for each sensitivity analysis and to Supplementary Figure 9 to see which 368 patients are excluded from each sensitivity analysis. 369

370

371 Supplementary Figure 9. Model estimate sensitivity analyses demonstrated that results 372 were overall unchanged after excluding populations of potential outliers. The final model 373 ( $\tau = 5$  weeks) was fit on three clinically interesting sub-populations to assess if the influence of

374 potential outlier data. Separate models were fit that excluded (a) participants reporting prior PrEP use (<10 days overlap between last PrEP use and estimated date of detected HIV 375 infection), (b) participants with plasma viral load "blips" (defined as a one-time viral load >1000 376 copies/mL or two consecutive viral loads >100 copies/mL between weeks 0-24), and (c) 377 378 participants with sudden increases in HIV intact DNA (defined as >50% increase between two 379 consecutive measurements of HIV intact DNA during weeks 0-24). Models were fit using the cohort data (grey lines), but not the potential outlier data (red lines). The resulting predict 380 average participant HIV reservoir decay patterns are shown as thick black lines. Refer to 381 Supplementary Table 2 to get the sample sizes and half-life estimates for each sensitivity 382 383 analysis.

384

Supplementary Figure 10. Predicted versus observed plots show good model performance for both HIV intact and defective DNA. Validation for the final models for intact and defective HIV DNA decay was initially performed by looking at the plots of predicted vs observed HIV DNA counts. These plots show that both models produce relatively unbiased estimates across the observed range of HIV DNA counts and that the residual variance in the defective reservoir is much higher than the intact reservoir. A dashed, red line at y=x is added to help interpret the model fits.

392

393 Supplementary Table 1. Model estimates of HIV intact and defective DNA decay rates 394 from baseline models. Baseline models include random intercepts for each participant but are 395 otherwise unadjusted for clinical covariates. Model estimates are provided for discrete periods 396 of ART suppression after initial treatment initiation: weeks 0 up to  $\tau = 5$  and for weeks after  $\tau$ .

397

398 Supplementary Table 2. Model estimates of HIV intact and defective DNA decay rates 399 from models adjusted for initial CD4+ T cell count, pre-ART HIV RNA, and timing of ART

400	initiation. Models also include a random intercept for each participant. Model estimates are
401	provided for discrete periods of ART suppression after initial treatment initiation: weeks 0 up to
402	$\tau$ = 5 and for weeks after $\tau$ .

403

Supplementary Table 3. Changes in HIV decay rates of intact and defective DNA
associated with timing of ART initiation. Faster decay rates in both intact and defective HIV
DNA during phase 1 are associated with lower delay in ART initiation. Intact, but not defective,
HIV DNA have faster predicted decay rates associated with lower delay in ART initiation.

408

Supplementary Table 4. Changes in the intact and defective HIV DNA reservoir size associated with initial CD4+ T cell count and pre-ART viral load. Table values are log<sub>10</sub> adjustments to the viral reservoir size at each clinical parameter. Higher initial CD4+ T cell count and lower pre-ART viral load are associated with smaller viral reservoirs. Additional estimates can be taken from Figure 3.